lanthanum carbonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4585 587-26-8

Description:

MoleculeDescription

Synonyms:

  • lanthanum carbonate
  • fosrenol
a phosphate binder used for hyperphosphatemia treatment in end-stage renal disease
  • Molecular weight: 457.84
  • Formula: C3La2O9
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 63.19
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2.25 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 26, 2004 FDA SHIRE LLC
Oct. 16, 2008 PMDA Bayer Yakuhin

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Shunt stenosis 340.88 23.89 51 2735 489 63485747
Shunt occlusion 249.24 23.89 40 2746 625 63485611
Nephrogenic systemic fibrosis 125.73 23.89 31 2755 4525 63481711
Blood phosphorus increased 79.73 23.89 20 2766 3125 63483111
Peritonitis 74.14 23.89 28 2758 17126 63469110
Skin induration 69.43 23.89 18 2768 3205 63483031
Blood parathyroid hormone increased 51.33 23.89 14 2772 3024 63483212
Skin hypertrophy 49.80 23.89 14 2772 3377 63482859
Skin tightness 46.47 23.89 14 2772 4302 63481934
Peripheral arterial occlusive disease 42.54 23.89 13 2773 4188 63482048
Skin fibrosis 40.12 23.89 9 2777 871 63485365
Death 37.15 23.89 62 2724 374319 63111917
Angina unstable 32.16 23.89 12 2774 7083 63479153
Hypocalcaemia 32.11 23.89 19 2767 31694 63454542
Shunt malfunction 31.13 23.89 5 2781 78 63486158
Joint contracture 29.38 23.89 8 2778 1716 63484520
Dialysis 27.68 23.89 12 2774 10415 63475821
Scar 27.51 23.89 13 2773 13769 63472467
Vomiting 27.20 23.89 69 2717 559548 62926688
Ileus 26.70 23.89 13 2773 14712 63471524
Peritonitis bacterial 24.88 23.89 9 2777 4870 63481366
Shunt infection 24.21 23.89 4 2782 75 63486161

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 487.90 22.87 144 7290 8457 34941040
Shunt stenosis 427.07 22.87 82 7352 700 34948797
Appendicitis 426.39 22.87 148 7286 14659 34934838
Cardiogenic shock 335.51 22.87 146 7288 26472 34923025
Stress 323.43 22.87 148 7286 30199 34919298
Shunt occlusion 270.03 22.87 57 7377 813 34948684
Ascites 266.16 22.87 149 7285 46422 34903075
Abdominal distension 257.47 22.87 158 7276 58334 34891163
Ventricular fibrillation 244.56 22.87 112 7322 22842 34926655
Multiple organ dysfunction syndrome 198.34 22.87 149 7285 76417 34873080
Hyponatraemia 186.00 22.87 148 7286 82543 34866954
Constipation 167.54 22.87 174 7260 136808 34812689
General physical health deterioration 151.53 22.87 160 7274 128109 34821388
Abdominal pain 148.74 22.87 178 7256 163440 34786057
Sepsis 142.92 22.87 176 7258 166385 34783112
Vomiting 126.49 22.87 204 7230 247417 34702080
Dry mouth 106.38 22.87 71 7363 30094 34919403
Myasthenia gravis 90.27 22.87 39 7395 6901 34942596
X-ray abnormal 85.64 22.87 20 7414 461 34949036
Nausea 85.38 22.87 208 7226 339700 34609797
Blood uric acid increased 84.04 22.87 41 7393 9583 34939914
Peripheral arterial occlusive disease 76.36 22.87 33 7401 5841 34943656
Hyperphosphataemia 67.92 22.87 28 7406 4409 34945088
Drug therapy 51.28 22.87 16 7418 1125 34948372
Analgesic therapy 49.10 22.87 15 7419 983 34948514
Blood cholesterol increased 48.64 22.87 38 7396 20505 34928992
Product residue present 47.77 22.87 19 7415 2727 34946770
Incorrect route of product administration 47.67 22.87 33 7401 14812 34934685
Acute kidney injury 47.29 22.87 5 7429 304983 34644514
Nephrogenic systemic fibrosis 47.19 22.87 21 7413 3984 34945513
Shunt infection 45.37 22.87 9 7425 92 34949405
Sleep disorder therapy 44.53 22.87 14 7420 1009 34948488
Fatigue 39.21 22.87 15 7419 370638 34578859
X-ray gastrointestinal tract abnormal 37.28 22.87 5 7429 0 34949497
Blood phosphorus increased 36.76 22.87 22 7412 7699 34941798
Somnolence 36.60 22.87 76 7358 111040 34838457
Iron deficiency 35.55 22.87 19 7415 5362 34944135
Dialysis hypotension 34.70 22.87 6 7428 26 34949471
Haemoglobin increased 34.25 22.87 16 7418 3393 34946104
Peritonitis 33.90 22.87 28 7406 16337 34933160
Drug ineffective 32.19 22.87 30 7404 456721 34492776
Hyperparathyroidism secondary 31.34 22.87 12 7422 1556 34947941
Blood parathyroid hormone increased 28.17 22.87 11 7423 1503 34947994
Shunt aneurysm 28.17 22.87 5 7429 26 34949471
Aplasia pure red cell 27.97 22.87 17 7417 6115 34943382
Wrong technique in product usage process 27.45 22.87 36 7398 35950 34913547
Hypophosphataemia 27.41 22.87 21 7413 11005 34938492
Condition aggravated 27.05 22.87 96 7338 192100 34757397
Neuralgia 25.50 22.87 23 7411 15090 34934407
Bacterial infection 25.00 22.87 24 7410 17039 34932458
Hypocalcaemia 24.53 22.87 28 7406 24261 34925236
Gangrene 24.28 22.87 14 7420 4572 34944925
Mucosal atrophy 23.31 22.87 5 7429 77 34949420
Peritonitis bacterial 23.01 22.87 15 7419 6095 34943402

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Shunt stenosis 756.48 20.85 133 9446 1258 79733551
Appendicolith 564.94 20.85 143 9436 8408 79726401
Shunt occlusion 494.56 20.85 94 9485 1410 79733399
Appendicitis 463.82 20.85 149 9430 20645 79714164
Cardiogenic shock 351.70 20.85 146 9433 41768 79693041
Ascites 278.04 20.85 149 9430 75413 79659396
Ventricular fibrillation 273.76 20.85 113 9466 31813 79702996
Stress 270.74 20.85 149 9430 79463 79655346
Abdominal distension 233.82 20.85 157 9422 119493 79615316
Multiple organ dysfunction syndrome 207.10 20.85 146 9433 120100 79614709
Sepsis 181.76 20.85 191 9388 269237 79465572
Hyponatraemia 164.58 20.85 150 9429 177698 79557111
Constipation 158.48 20.85 182 9397 282868 79451941
General physical health deterioration 152.43 20.85 176 9403 275062 79459747
Abdominal pain 142.97 20.85 203 9376 389366 79345443
Peripheral arterial occlusive disease 127.76 20.85 45 9534 8213 79726596
Vomiting 125.82 20.85 258 9321 665570 79069239
Nephrogenic systemic fibrosis 104.65 20.85 36 9543 6124 79728685
Myasthenia gravis 96.53 20.85 39 9540 10360 79724449
Hyperphosphataemia 92.01 20.85 33 9546 6343 79728466
Blood uric acid increased 90.32 20.85 40 9539 13320 79721489
Peritonitis 75.12 20.85 45 9534 27991 79706818
Product residue present 73.28 20.85 24 9555 3512 79731297
Dry mouth 73.07 20.85 70 9509 87949 79646860
Shunt infection 68.09 20.85 13 9566 199 79734610
Nausea 66.58 20.85 258 9321 956938 78777871
X-ray abnormal 65.18 20.85 25 9554 5788 79729021
Blood parathyroid hormone increased 61.90 20.85 21 9558 3424 79731385
Drug therapy 59.50 20.85 16 9563 1185 79733624
Analgesic therapy 57.41 20.85 15 9564 994 79733815
Fatigue 52.75 20.85 23 9556 929704 78805105
Skin induration 52.67 20.85 20 9559 4505 79730304
Sleep disorder therapy 52.42 20.85 14 9565 1010 79733799
Angina unstable 50.79 20.85 29 9550 16498 79718311
Blood phosphorus increased 48.33 20.85 24 9555 10323 79724486
Drug ineffective 48.13 20.85 36 9543 1080877 78653932
Incorrect route of product administration 47.80 20.85 37 9542 34892 79699917
Hypocalcaemia 47.78 20.85 43 9536 49881 79684928
Skin hypertrophy 47.52 20.85 19 9560 4909 79729900
Haemoglobin increased 46.79 20.85 20 9559 6112 79728697
X-ray gastrointestinal tract abnormal 45.73 20.85 6 9573 3 79734806
Shunt aneurysm 43.49 20.85 7 9572 36 79734773
Acute kidney injury 40.24 20.85 7 9572 519397 79215412
Somnolence 39.47 20.85 88 9491 238893 79495916
Cerebral infarction 39.16 20.85 37 9542 45639 79689170
Aplasia pure red cell 39.11 20.85 19 9560 7791 79727018
Shunt malfunction 36.07 20.85 8 9571 263 79734546
Skin tightness 35.61 20.85 16 9563 5506 79729303
Hyperparathyroidism secondary 35.50 20.85 13 9566 2647 79732162
Diverticulum intestinal haemorrhagic 33.66 20.85 14 9565 3997 79730812
Iron deficiency 33.55 20.85 19 9560 10635 79724174
Peritonitis bacterial 32.69 20.85 18 9561 9549 79725260
Mucosal atrophy 32.63 20.85 6 9573 74 79734735
Joint contracture 32.45 20.85 12 9567 2512 79732297
Ileus 32.07 20.85 26 9553 26185 79708624
Dialysis hypotension 31.93 20.85 6 9573 84 79734725
Hypophosphataemia 31.47 20.85 23 9556 19890 79714919
Gangrene 31.00 20.85 17 9562 8947 79725862
Dialysis 30.72 20.85 22 9557 18440 79716369
Wrong technique in product usage process 30.68 20.85 41 9538 73834 79660975
Bacterial infection 30.03 20.85 27 9552 31253 79703556
Shunt blood flow excessive 27.40 20.85 4 9575 9 79734800
Skin fibrosis 26.24 20.85 9 9570 1515 79733294
Large intestine polyp 25.51 20.85 17 9562 12691 79722118
Cardiac failure 25.51 20.85 57 9522 154785 79580024
Toxicity to various agents 24.50 20.85 10 9569 421530 79313279
Joint swelling 24.38 20.85 3 9576 288643 79446166
Blood cholesterol increased 23.96 20.85 39 9540 83681 79651128
Fibrosis 23.86 20.85 12 9567 5297 79729512
Sudden death 22.74 20.85 20 9559 22491 79712318
Gastric mucosal lesion 21.91 20.85 7 9572 946 79733863
Renal cyst infection 21.40 20.85 5 9574 208 79734601
Bezoar 21.28 20.85 9 9570 2679 79732130
Enterocolitis 21.22 20.85 16 9563 14496 79720313
Neuralgia 21.20 20.85 23 9556 33361 79701448
Weight increased 20.89 20.85 4 9575 277382 79457427

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V03AE03 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Drugs for treatment of hyperkalemia and hyperphosphatemia

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Renal Osteodystrophy with Hyperphosphatemia indication
Hyperphosphatemia associated with administration of FGFR inhibitor indication
Constipation contraindication 14760008 DOID:2089
Fecal impaction contraindication 44635007
Intestinal obstruction contraindication 81060008 DOID:8437
Gastrointestinal obstruction contraindication 126765001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 1GM BASE FOSRENOL TAKEDA PHARMS USA N021468 Nov. 23, 2005 RX TABLET, CHEWABLE ORAL 7381428 Aug. 26, 2024 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
EQ 250MG BASE FOSRENOL TAKEDA PHARMS USA N021468 Oct. 26, 2004 DISCN TABLET, CHEWABLE ORAL 7381428 Aug. 26, 2024 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
EQ 500MG BASE FOSRENOL TAKEDA PHARMS USA N021468 Oct. 26, 2004 RX TABLET, CHEWABLE ORAL 7381428 Aug. 26, 2024 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
EQ 750MG BASE FOSRENOL TAKEDA PHARMS USA N021468 Nov. 23, 2005 RX TABLET, CHEWABLE ORAL 7381428 Aug. 26, 2024 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4021512 VUID
N0000179691 NUI
4021512 VANDF
CHEMBL2096647 ChEMBL_ID
C119467 MESH_SUPPLEMENTAL_RECORD_UI
DB06792 DRUGBANK_ID
490D9F069T UNII
234416 RXNORM
18979 MMSL
35731 MMSL
62060 MMSL
79763 MMSL
d05395 MMSL
008767 NDDF
414570008 SNOMEDCT_US
414571007 SNOMEDCT_US
C0768119 UMLSCUI
168924 PUBCHEM_CID
54451-24-0 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5938 TABLET, CHEWABLE 500 mg ORAL ANDA 27 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5939 TABLET, CHEWABLE 750 mg ORAL ANDA 27 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5940 TABLET, CHEWABLE 1000 mg ORAL ANDA 27 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-252 TABLET, CHEWABLE 500 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-252 TABLET, CHEWABLE 500 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-253 TABLET, CHEWABLE 750 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-253 TABLET, CHEWABLE 750 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-254 TABLET, CHEWABLE 1000 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-254 TABLET, CHEWABLE 1000 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-256 POWDER 750 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-256 POWDER 750 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-257 POWDER 1000 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-257 POWDER 1000 mg ORAL NDA 31 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 66993-422 TABLET, CHEWABLE 500 mg ORAL NDA authorized generic 31 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 66993-422 TABLET, CHEWABLE 500 mg ORAL NDA authorized generic 31 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 66993-423 TABLET, CHEWABLE 750 mg ORAL NDA authorized generic 31 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 66993-423 TABLET, CHEWABLE 750 mg ORAL NDA authorized generic 31 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 66993-424 TABLET, CHEWABLE 1000 mg ORAL NDA authorized generic 31 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 66993-424 TABLET, CHEWABLE 1000 mg ORAL NDA authorized generic 31 sections
Lanthanum Carbonate Human Prescription Drug Label 1 68180-819 TABLET, CHEWABLE 500 mg ORAL ANDA 26 sections
Lanthanum Carbonate Human Prescription Drug Label 1 68180-820 TABLET, CHEWABLE 750 mg ORAL ANDA 26 sections
Lanthanum Carbonate Human Prescription Drug Label 1 68180-821 TABLET, CHEWABLE 1000 mg ORAL ANDA 26 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 69097-934 TABLET, CHEWABLE 500 mg ORAL ANDA 30 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 69097-934 TABLET, CHEWABLE 500 mg ORAL ANDA 30 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 69097-935 TABLET, CHEWABLE 750 mg ORAL ANDA 30 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 69097-935 TABLET, CHEWABLE 750 mg ORAL ANDA 30 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 69097-936 TABLET, CHEWABLE 1000 mg ORAL ANDA 30 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 69097-936 TABLET, CHEWABLE 1000 mg ORAL ANDA 30 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 76282-476 TABLET, CHEWABLE 500 mg ORAL ANDA 30 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 76282-476 TABLET, CHEWABLE 500 mg ORAL ANDA 30 sections